RxDoctor Payments Data

Joshua Kroll, DO

Family Medicine · Traverse City, MINPI 1700378494

Payments from drug & device makers

$564in general payments, 2019–2025

Across 31 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$156
  • Novo Nordisk$80
  • Pfizer$65
  • Dexcom, Inc.$62
  • Inspire Medical Systems, Inc.$47
  • Astellas Pharma US Inc$29
  • plus $124 from 7 others

What the payments were for

  • Food & beverage$55098%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$564 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$123,097
Medicare patients
307
Services billed
3,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$155,720
XareltoRivaroxaban34$35,271
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$32,817
JardianceEmpagliflozin31$26,972
OzempicSemaglutide15$24,251
TrulicityDulaglutide12$20,013
JanuviaSitagliptin Phosphate16$16,614
Breo ElliptaFluticasone/Vilanterol26$13,137
ArexvyRsvpref3 Antigen/As01e/Pf34$10,779
Repatha SyringeEvolocumab13$8,149
Atorvastatin Calcium536$8,059
Rosuvastatin Calcium311$5,664
SymbicortBudesonide/Formoterol Fumarate12$5,660
ShingrixVaricella-Zoster Ge/As01b/Pf25$5,628
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$155,720117 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$17$62,361112 claims
Novo NordiskOzempic$80$24,25115 claims
Lilly USA, LLCTrulicity$19$20,01312 claims
AstraZenecaSymbicort$18$5,66012 claims
AbbVieSynthroid$156$1,50116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →